While SIRT1, SIRT2, and SIRT5 may have tumour-promoting or tumour-suppressing effects depending on the tumour histology and cellular context [32], the NCI-60 panel included melanoma cell lines, and therefore the differences in SIRT2 associations with dasatinib response may be caused by factors other than tumour specificity. The gene discussed is SIRT1; the disease is neoplasm.